Beijing Tiannuo Jiancheng Pharmaceutical Technology Co., Ltd.

The main purpose of Phase Ia: 1. Evaluate the safety and tolerability of CM369 in subjects with advanced solid tumors and hematological tumors 2. Determine the maximum tolerated dose (MTD) of CM369 (if applicable) The main purpose of Phase Ib: 1. Preliminary evaluation of the effectiveness of CM369 in subjects with advanced solid tumors and hematological tumors through ORR 2. Determine the recommended dose for Phase II clinical trials (RP2D)

Phase I study objectives Primary objectives: 1. To evaluate the safety and tolerability of CM355 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). 2. To determine the Phase II recommended dose (RP2D) and/or maximum tolerated dose (MTD) of CM355 in patients with R/R B-NHL (if applicable). Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of CM355 in patients with R/R B-NHL. 2. To evaluate the immunogenicity characteristics of CM355. 3. To preliminarily evaluate the anti-tumor efficacy of CM355 in the treatment of patients with R/R B-NHL. Exploratory objectives: 1. To evaluate the changes in pharmacodynamic (PD) markers related to CM355 treatment and their correlation analysis with PK and/or clinical outcomes. Phase II study objectives Primary objectives: 1. To evaluate the effectiveness of CM355 in the treatment of patients with R/R B-NHL at the Phase II recommended dose (RP2D). Secondary objectives: 1. To evaluate the depth, durability, safety, PK characteristics, and immunogenicity characteristics of CM355 in the treatment of R/R B-NHL patients at the Phase II recommended dose (RP2D). Exploratory objectives: 1. To evaluate the changes in PD biomarkers related to CM355 treatment and their correlation with PK and/or clinical outcomes.